SLITRK5

Summary

SLITRK5 (SLIT and NTRK like family member 5, HGNC:20295) is a protein-coding gene on chromosome 13q31.2, encoding SLIT and NTRK-like protein 5 (O94991). Suppresses neurite outgrowth.

Members of the SLITRK family, such as SLITRK5, are integral membrane proteins with 2 N-terminal leucine-rich repeat (LRR) domains similar to those of SLIT proteins (see SLIT1; MIM 603742). Most SLITRKs, including SLITRK5, also have C-terminal regions that share homology with neurotrophin receptors (see NTRK1; MIM 191315). SLITRKs are expressed predominantly in neural tissues and have neurite-modulating activity (Aruga et al., 2003 [PubMed 14557068]).

Source: NCBI Gene 26050 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 166 total — 1 likely-pathogenic
• MANE Select transcript: NM_001384609

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20295
Approved symbol	SLITRK5
Name	SLIT and NTRK like family member 5
Location	13q31.2
Locus type	gene with protein product
Status	Approved
Aliases	bA364G4.2, KIAA0918
Ensembl gene	ENSG00000165300
Ensembl biotype	protein_coding
OMIM	609680
Entrez	26050

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000325089, ENST00000683689, ENST00000933099, ENST00000933100

RefSeq mRNA: 3 — MANE Select: NM_001384609 NM_001384609, NM_001384610, NM_015567

CCDS: CCDS9465

Canonical transcript exons

ENST00000683689 — 2 exons

Exon	Start	End
ENSE00003917088	87675381	87679616
ENSE00003921311	87671371	87672209

Expression profiles

Bgee: expression breadth ubiquitous, 168 present calls, max score 95.55.

FANTOM5 (CAGE): breadth broad, TPM avg 3.1283 / max 125.3734, expressed in 612 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
135602	2.6837	585
135606	0.1099	57
135604	0.1058	49
135607	0.0898	48
135603	0.0848	37
135605	0.0543	33

Top tissues by expression

270 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	95.55	gold quality
frontal pole	UBERON:0002795	94.32	gold quality
Brodmann (1909) area 23	UBERON:0013554	93.81	gold quality
parotid gland	UBERON:0001831	93.43	gold quality
Brodmann (1909) area 10	UBERON:0013541	93.31	gold quality
orbitofrontal cortex	UBERON:0004167	93.07	gold quality
Brodmann (1909) area 46	UBERON:0006483	92.47	gold quality
postcentral gyrus	UBERON:0002581	90.85	gold quality
parietal lobe	UBERON:0001872	90.16	gold quality
superior frontal gyrus	UBERON:0002661	89.19	gold quality
CA1 field of hippocampus	UBERON:0003881	89.14	gold quality
entorhinal cortex	UBERON:0002728	88.60	gold quality
middle frontal gyrus	UBERON:0002702	88.34	gold quality
paraflocculus	UBERON:0005351	87.96	gold quality
endothelial cell	CL:0000115	84.83	gold quality
cerebellar vermis	UBERON:0004720	82.88	gold quality
occipital lobe	UBERON:0002021	82.28	gold quality
primary visual cortex	UBERON:0002436	81.59	gold quality
trigeminal ganglion	UBERON:0001675	80.79	gold quality
dorsal root ganglion	UBERON:0000044	79.71	gold quality
germinal epithelium of ovary	UBERON:0001304	78.78	gold quality
cortical plate	UBERON:0005343	78.61	gold quality
frontal cortex	UBERON:0001870	77.89	gold quality
substantia nigra pars compacta	UBERON:0001965	77.39	gold quality
cerebral cortex	UBERON:0000956	76.69	gold quality
neocortex	UBERON:0001950	76.50	gold quality
prefrontal cortex	UBERON:0000451	76.35	gold quality
substantia nigra pars reticulata	UBERON:0001966	75.92	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	75.68	silver quality
dorsolateral prefrontal cortex	UBERON:0009834	74.81	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.96
E-MTAB-7249	no	272.31

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 6)

• This study did not find any evidence supporting the association of Tourette syndrome and SLITRK5. (PMID:25426764)
• Mutation in SLITRK5 gene is Associated with Obsessive Compulsive Disorder (PMID:28085938)
• SLITRK5 is a negative regulator of hedgehog signaling in osteoblasts. (PMID:34326333)
• MUC21 controls melanoma progression via regulating SLITRK5 and hedgehog signaling pathway. (PMID:35579188)
• The Role of SliTrk5 in Central Nervous System. (PMID:35872846)
• Upregulation of SLITRK5 in patients with epilepsy and in a rat model. (PMID:36811190)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	slitrk5b	ENSDARG00000074153
danio_rerio	slitrk5a	ENSDARG00000103359
mus_musculus	Slitrk5	ENSMUSG00000033214
rattus_norvegicus	Slitrk5	ENSRNOG00000009649

Paralogs (25): SLITRK3 (ENSG00000121871), LRFN3 (ENSG00000126243), LRFN1 (ENSG00000128011), SLIT2 (ENSG00000145147), LRFN2 (ENSG00000156564), LRRC38 (ENSG00000162494), LRFN5 (ENSG00000165379), LRTM2 (ENSG00000166159), LINGO1 (ENSG00000169783), LRRN2 (ENSG00000170382), LRRN3 (ENSG00000173114), LRFN4 (ENSG00000173621), LINGO2 (ENSG00000174482), LRRN1 (ENSG00000175928), SLITRK1 (ENSG00000178235), GP5 (ENSG00000178732), SLITRK4 (ENSG00000179542), LRRC55 (ENSG00000183908), SLIT3 (ENSG00000184347), SLITRK6 (ENSG00000184564), SLITRK2 (ENSG00000185985), LRRC70 (ENSG00000186105), SLIT1 (ENSG00000187122), TLR9 (ENSG00000239732), TPBGL (ENSG00000261594)

Protein

Protein identifiers

SLIT and NTRK-like protein 5 — O94991 (reviewed: O94991)

Alternative names: Leucine-rich repeat-containing protein 11

All UniProt accessions (1): O94991

UniProt curated annotations — full annotation on UniProt →

Function. Suppresses neurite outgrowth.

Subcellular location. Membrane.

Tissue specificity. Expressed predominantly in the cerebral cortex of the brain but also at low levels in the spinal cord and medulla.

Similarity. Belongs to the SLITRK family.

Isoforms (2)

UniProt ID	Names	Canonical?
O94991-1	1	yes
O94991-2	2

RefSeq proteins (3): NP_001371538, NP_001371539, NP_056382 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000483	Cys-rich_flank_reg_C	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily

Pfam: PF13855

UniProt features (27 total): repeat 12, domain 3, topological domain 2, region of interest 2, glycosylation site 2, splice variant 2, signal peptide 1, chain 1, compositionally biased region 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O94991-F1	65.92	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 103, 644

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-388844	Receptor-type tyrosine-protein phosphatases
R-HSA-9013404	RAC2 GTPase cycle
R-HSA-9013423	RAC3 GTPase cycle
R-HSA-112316	Neuronal System
R-HSA-162582	Signal Transduction
R-HSA-194315	Signaling by Rho GTPases
R-HSA-6794362	Protein-protein interactions at synapses
R-HSA-9012999	RHO GTPase cycle
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3

MSigDB gene sets: 193 (showing top): GOBP_DENDRITE_DEVELOPMENT, RRAGTTGT_UNKNOWN, LEE_NEURAL_CREST_STEM_CELL_DN, FREAC2_01, GOBP_BEHAVIOR, GOBP_SYNAPSE_ASSEMBLY, GOBP_ADULT_BEHAVIOR, GOBP_POSITIVE_REGULATION_OF_SYNAPSE_ASSEMBLY, GOBP_NEUROGENESIS, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, FOXO4_01, AP2_Q3, FOXO1_01, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS

GO Biological Process (12): chemical synaptic transmission (GO:0007268), axonogenesis (GO:0007409), grooming behavior (GO:0007625), response to xenobiotic stimulus (GO:0009410), striatum development (GO:0021756), adult behavior (GO:0030534), skin development (GO:0043588), dendrite morphogenesis (GO:0048813), positive regulation of synapse assembly (GO:0051965), circulatory system development (GO:0072359), synaptic membrane adhesion (GO:0099560), regulation of trans-synaptic signaling by BDNF, modulating synaptic transmission (GO:0150035)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): plasma membrane (GO:0005886), signaling receptor complex (GO:0043235), postsynaptic density membrane (GO:0098839), glutamatergic synapse (GO:0098978), membrane (GO:0016020), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
RHO GTPase cycle	2
Protein-protein interactions at synapses	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Neuronal System	1
Signaling by Rho GTPases	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell morphogenesis involved in neuron differentiation	2
neuron projection morphogenesis	2
behavior	2
anterograde trans-synaptic signaling	1
axon development	1
response to chemical	1
subpallium development	1
anatomical structure development	1
animal organ development	1
dendrite development	1
synapse assembly	1
positive regulation of nervous system development	1
regulation of synapse assembly	1
positive regulation of cell junction assembly	1
system development	1
synapse organization	1
cell-cell adhesion	1
modulation of chemical synaptic transmission	1
trans-synaptic signaling by BDNF, modulating synaptic transmission	1
binding	1
membrane	1
cell periphery	1
protein-containing complex	1
postsynaptic density	1
postsynaptic membrane	1
postsynaptic specialization membrane	1
synapse	1
cellular anatomical structure	1
cell junction	1

Protein interactions and networks

STRING

1484 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLITRK5	DLGAP3	O95886	933
SLITRK5	NTRK2	Q16620	586
SLITRK5	NTRK1	P04629	576
SLITRK5	HOXB8	P17481	573
SLITRK5	PTPRS	Q13332	554
SLITRK5	FRMPD1	Q5SYB0	460
SLITRK5	CPNE5	Q9HCH3	457
SLITRK5	TMEM51	Q9NW97	445
SLITRK5	DLGAP1	P78335	430
SLITRK5	SLC1A1	P43005	428
SLITRK5	MCTP2	Q6DN12	424
SLITRK5	FAT4	Q6V0I7	418
SLITRK5	FHIT	P49789	411
SLITRK5	RAB28	P51157	410
SLITRK5	SPATS2L	Q9NUQ6	410

IntAct

47 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
BOLA2-SMG1P6	SLITRK5	psi-mi:“MI:0915”(physical association)	0.560
SLITRK5	CLCNKA	psi-mi:“MI:0915”(physical association)	0.560
LRFN4	RIMOC1	psi-mi:“MI:0914”(association)	0.530
SPACA1	GOLIM4	psi-mi:“MI:0914”(association)	0.530
SLC39A4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
SLC39A4	TMEM120B	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
SPACA1	ESYT2	psi-mi:“MI:0914”(association)	0.350
TCTN2	TMEM131L	psi-mi:“MI:0914”(association)	0.350
IL22RA1	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
TAS1R2	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
ATP1B1	TM9SF1	psi-mi:“MI:0914”(association)	0.350
NRROS	HS6ST1	psi-mi:“MI:0914”(association)	0.350
AIMP1	IGF2BP3	psi-mi:“MI:0914”(association)	0.350
AIMP1	TRAFD1	psi-mi:“MI:0914”(association)	0.350
CACYBP	VPS37C	psi-mi:“MI:0914”(association)	0.350
CACYBP	PSMD11	psi-mi:“MI:0914”(association)	0.350
CAPRIN1	VPS37C	psi-mi:“MI:0914”(association)	0.350
CAPRIN1	SDCBP	psi-mi:“MI:0914”(association)	0.350
CFL2	VPS37C	psi-mi:“MI:0914”(association)	0.350
CFL2	PSMD11	psi-mi:“MI:0914”(association)	0.350
CSDE1	VPS37C	psi-mi:“MI:0914”(association)	0.350
EIF4A1	SNAP23	psi-mi:“MI:0914”(association)	0.350

BioGRID (65): SLITRK5 (Affinity Capture-MS), SLITRK5 (Affinity Capture-MS), SLITRK5 (Affinity Capture-MS), SLITRK5 (Affinity Capture-MS), SLITRK5 (Affinity Capture-MS), SLITRK5 (Affinity Capture-RNA), SLITRK5 (Proximity Label-MS), SLITRK5 (Proximity Label-MS), SLITRK5 (Proximity Label-MS), BOLA2B (Two-hybrid), BOLA2 (Two-hybrid), CLCNKA (Two-hybrid), SLITRK5 (Proximity Label-MS), SLITRK5 (Affinity Capture-MS), SLITRK5 (Affinity Capture-MS)

ESM2 similar proteins: A1XQX3, A1XQY0, A1XQY3, A2ALI5, A6QLD2, B5X216, D0PRN4, E9PUN2, O35181, O75151, O94933, O94991, P0C7U0, P15379, P23470, P49415, P56975, P58401, P80560, Q05909, Q3SXY7, Q3UH99, Q3V1G4, Q4W8E7, Q58EG3, Q5EGE1, Q5R3F8, Q5R5B8, Q63376, Q63475, Q68BL8, Q68FM6, Q6QD51, Q6ZSJ9, Q76KF0, Q80Z10, Q810B7, Q810B9, Q8AXP2, Q8C8T7

Diamond homologs: A8WGA3, B1H134, B1H234, D3ZTV3, D4ABX8, F1NUK7, G5EFX6, O42235, O43155, O55226, O60938, O75093, O88279, O88280, O94769, O94991, P04629, P13224, P14770, P24014, P50608, P50609, P56400, P59383, P83503, Q04785, Q06828, Q3UHC2, Q5R6T0, Q5RAC4, Q5RI43, Q6RKD8, Q6WRH9, Q70AK3, Q7Z2Q7, Q80TR4, Q80XU8, Q810B7, Q810C1, Q8BGT1

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
SLITRK5	“down-regulates activity”	SHH	binding
SLITRK5	“down-regulates activity”	PTCH1	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

166 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	150
Likely benign	10
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
402167	NM_001384609.1(SLITRK5):c.2515G>C (p.Glu839Gln)	Likely pathogenic

SpliceAI

855 predictions. Top by Δscore:

Variant	Effect	Δscore
13:87672824:GG:G	donor_gain	0.9900
13:87672825:GG:G	donor_gain	0.9900
13:87672826:G:GA	donor_loss	0.9900
13:87672826:G:GG	donor_gain	0.9900
13:87672827:T:G	donor_loss	0.9900
13:87674635:C:G	donor_gain	0.9900
13:87675376:TACA:T	acceptor_loss	0.9900
13:87675379:A:G	acceptor_loss	0.9900
13:87675380:G:T	acceptor_loss	0.9900
13:87672822:CTGG:C	donor_gain	0.9800
13:87674641:G:GA	donor_gain	0.9800
13:87674687:T:TA	donor_gain	0.9800
13:87674688:AGTGA:A	donor_gain	0.9800
13:87675378:CAGG:C	acceptor_gain	0.9800
13:87675379:A:AG	acceptor_gain	0.9800
13:87675379:AGGA:A	acceptor_gain	0.9800
13:87675379:AGGAG:A	acceptor_gain	0.9800
13:87675380:G:GG	acceptor_gain	0.9800
13:87675380:GGA:G	acceptor_gain	0.9800
13:87675380:GGAG:G	acceptor_gain	0.9800
13:87675380:GGAGG:G	acceptor_gain	0.9800
13:87688235:AGATG:A	acceptor_gain	0.9800
13:87675377:ACAGG:A	acceptor_gain	0.9700
13:87675379:AG:A	acceptor_gain	0.9700
13:87675380:GG:G	acceptor_gain	0.9700
13:87672823:TGG:T	donor_gain	0.9600
13:87672824:GGG:G	donor_gain	0.9600
13:87680045:A:AG	acceptor_gain	0.9600
13:87680046:G:GG	acceptor_gain	0.9600
13:87688234:TAG:T	acceptor_gain	0.9600

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000212859 (13:87671166 T>C), RS1000486817 (13:87672887 G>A,T), RS1000553700 (13:87671947 A>T), RS1000583114 (13:87672156 G>A,C), RS1000652540 (13:87671311 G>A), RS1000837861 (13:87672621 A>G), RS1001432538 (13:87671740 G>T), RS1001877271 (13:87677310 T>G), RS1001941376 (13:87675244 C>T), RS1001992164 (13:87675511 C>G,T), RS1002422804 (13:87671886 C>T), RS1002483329 (13:87671081 A>G), RS1002541571 (13:87674562 A>C,G), RS1002616978 (13:87674727 T>C), RS1002884553 (13:87674682 C>A)

Disease associations

OMIM: gene MIM:609680 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): autism spectrum disorder (MONDO:0005258)

Orphanet (1): NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST003124_5	Mild influenza (H1N1) infection	4.000000e-11
GCST005247_1	Male sexual orientation	8.000000e-07
GCST009391_2030	Metabolite levels	9.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:1001488	influenza A (H1N1)
EFO:0010371	lysophosphatidylethanolamine 22:6 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases methylation	7
sodium arsenite	increases expression, affects methylation, decreases expression, affects cotreatment, increases abundance	4
Air Pollutants	decreases expression, increases abundance	2
Benzo(a)pyrene	increases methylation, increases mutagenesis	2
Estradiol	affects cotreatment, decreases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
Particulate Matter	decreases expression, increases abundance	2
aristolochic acid I	decreases expression	1
ethylbenzene	affects cotreatment, decreases expression	1
methylmercuric chloride	decreases expression	1
trichostatin A	increases expression	1
arsenite	increases methylation	1
butyraldehyde	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
benzo(e)pyrene	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
licochalcone B	decreases expression	1
jinfukang	increases expression, affects cotreatment	1
NSC 689534	affects binding, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Temozolomide	decreases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Carbamazepine	affects expression	1
Cisplatin	affects cotreatment, increases expression	1
Copper	affects binding, decreases expression	1
Cytarabine	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder